Patent intelligence · US
US 12343350
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
Patent details — US 12343350
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 1, 2025
- Expiration
- Jun 26, 2045
- Applicant
- Windtree Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/5685, A61K45/06, A61K9/009
Quick answer
US 12343350 (Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)) is held by Windtree Therapeutics, Inc.. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Windtree Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/5685, A61K45/06, A61K9/009, A61P, A61P9/00
More from Windtree Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11583540
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 11197869
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 9554999
Lyophilization of synthetic liposomal pulmonary surfactant
granted
Frequently asked questions
What is US patent 12343350?
US 12343350 (Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)) is held by Windtree Therapeutics, Inc.. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12343350?
Windtree Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12343350 expire?
Our index shows an expiration date of Jun 26, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.